No Data
No Data
As of August 9th, wuhan hiteck biological pharma (300683.SZ) had a total of 11,568 shareholders.
On August 16, Gelunhui reported that Wuhan Hiteck Biological Pharma (300683.SZ) stated on the investor interaction platform that as of August 9, the number of shareholders in the company was 11,568.
As of July 10th, the number of shareholders of Wuhan Hiteck Biological Pharma (300683.SZ) was 11,374.
On July 16th, Gelunhui reported that as of July 10th, Wuhan Hiteck Biological Pharma (300683.SZ) had 11,374 shareholders on the investor interactive platform.
Wuhan Hiteck Biological Pharma (300683.SZ): its subsidiary plans to introduce external investors for a capital increase of 46 million yuan in Econ. Dev. Zone Sci. & Tech. Park.
On July 2nd, Gelunhui reported that on July 2nd, 2024, the company held the 16th meeting of the eighth board of directors and passed the proposal on introducing external investors to increase capital for the wholly-owned subsidiary. According to the company's strategic planning and business development needs, it plans to introduce external investor Wuhan Jingkai Kechuang Service Co., Ltd. (hereinafter referred to as "Jingkai Kechuang") to increase capital of 46 million yuan to the wholly-owned subsidiary, Wuhan Jingkai Hiteck Biological Industry Development Co., Ltd. (hereinafter referred to as "Jingkai Hiteck"). At the same time, the company plans to transfer the unpaid 6.8 million yuan subscribed capital contribution to 0 yuan as consideration.
Haite Biotech (300683.SZ): As of May 20, the number of shareholders of the company was 12,790
Gelonghui, May 23丨Haite Biotech (300683.SZ) said on the investor interactive platform that as of May 20, the number of shareholders of the company was 12,790.
Haite Biotech (300683.SZ): Commercial sales of the new injectable epneamin have begun
Glonghui, May 23丨Haite Biotech (300683.SZ) said on the investor interactive platform that commercial sales of the company's new injectable epneamin have begun, and the company will actively promote the marketing of this product to bring new profit growth points to the company.
Haite Biotech (300683.SZ): Commercial sales of the product CPT have recently begun
Gelonghui, May 9丨Haite Biotech (300683.SZ) said on the investor interactive platform that the company's product CPT has recently begun commercial sales.
No Data